Serina Therapeutics Stock Fundamentals
| SER Stock | 4.79 0.64 15.42% |
Serina Therapeutics fundamentals help investors to digest information that contributes to Serina Therapeutics' financial success or failures. It also enables traders to predict the movement of Serina Stock. The fundamental analysis module provides a way to measure Serina Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Serina Therapeutics stock.
As of 12/18/2024, Interest Expense is likely to grow to about 5.1 M, while Depreciation And Amortization is likely to drop slightly above 124.5 K. Serina | Select Account or Indicator |
Serina Therapeutics Company Return On Asset Analysis
Serina Therapeutics' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Serina Therapeutics Return On Asset | -0.45 |
Most of Serina Therapeutics' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Serina Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Serina Total Assets
Total Assets |
|
Based on the latest financial disclosure, Serina Therapeutics has a Return On Asset of -0.4529. This is 94.82% lower than that of the Biotechnology sector and 98.08% lower than that of the Health Care industry. The return on asset for all United States stocks is notably higher than that of the company.
Serina Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Serina Therapeutics's current stock value. Our valuation model uses many indicators to compare Serina Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Serina Therapeutics competition to find correlations between indicators driving Serina Therapeutics's intrinsic value. More Info.Serina Therapeutics is rated third in return on asset category among its peers. It is currently regarded as top stock in profit margin category among its peers . At this time, Serina Therapeutics' Net Loss is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Serina Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Serina Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Serina Therapeutics' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Serina Therapeutics could also be used in its relative valuation, which is a method of valuing Serina Therapeutics by comparing valuation metrics of similar companies.Serina Therapeutics is currently under evaluation in return on asset category among its peers.
Serina Fundamentals
| Return On Asset | -0.45 | ||||
| Profit Margin | (2.21) % | ||||
| Operating Margin | (75.80) % | ||||
| Current Valuation | 62.84 M | ||||
| Shares Outstanding | 8.88 M | ||||
| Shares Owned By Insiders | 58.14 % | ||||
| Shares Owned By Institutions | 2.30 % | ||||
| Number Of Shares Shorted | 27.52 K | ||||
| Price To Sales | 18.03 X | ||||
| Revenue | 142 K | ||||
| EBITDA | (9.78 M) | ||||
| Net Income | (14.8 M) | ||||
| Total Debt | 4.37 M | ||||
| Book Value Per Share | (1.86) X | ||||
| Cash Flow From Operations | (7.8 M) | ||||
| Short Ratio | 1.73 X | ||||
| Earnings Per Share | 0.14 X | ||||
| Market Capitalization | 57.2 M | ||||
| Total Asset | 11.96 M | ||||
| Retained Earnings | (131.01 M) | ||||
| Working Capital | 110.89 K | ||||
| Net Asset | 11.96 M |
About Serina Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Serina Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Serina Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Serina Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 1.00 | 0.95 | |
| Total Revenue | 142 K | 134.9 K | |
| Cost Of Revenue | 171 K | 162.4 K | |
| Stock Based Compensation To Revenue | 0.02 | 0.02 | |
| Sales General And Administrative To Revenue | 2.32 | 1.20 | |
| Research And Ddevelopement To Revenue | 4.25 | 4.03 | |
| Capex To Revenue | 0.02 | 0.02 | |
| Revenue Per Share | 0.13 | 0.13 | |
| Ebit Per Revenue | (70.14) | (73.65) |
Pair Trading with Serina Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Serina Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Serina Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Serina Stock
Moving against Serina Stock
| 0.73 | GILD | Gilead Sciences | PairCorr |
| 0.71 | BMY | Bristol Myers Squibb | PairCorr |
| 0.62 | DYAI | Dyadic International | PairCorr |
| 0.53 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
The ability to find closely correlated positions to Serina Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Serina Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Serina Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Serina Therapeutics to buy it.
The correlation of Serina Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Serina Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Serina Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Serina Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Serina Stock Analysis
When running Serina Therapeutics' price analysis, check to measure Serina Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Serina Therapeutics is operating at the current time. Most of Serina Therapeutics' value examination focuses on studying past and present price action to predict the probability of Serina Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Serina Therapeutics' price. Additionally, you may evaluate how the addition of Serina Therapeutics to your portfolios can decrease your overall portfolio volatility.